Amgen reported higher quarterly earnings on Wednesday, driven by a 24% rise in sales of products including cholesterol drug ...

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335. Amgen reported in-line topline sales for Q3, with most products as ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

Discover how Amgen is achieving a fully automated enterprise through strategic partnerships with Cognizant and UiPath to enhance efficiency.

Amgen’s third-quarter product sales grew 24% (or 8% excluding the October 2023 Horizon Therapeutics acquisition), with strong double-digit growth for key products including cholesterol-lowering ...

Amgen (NASDAQ:AMGN – Get Free Report) will be releasing its earnings data before the market opens on Wednesday, October 30th.

Amgen's acquisition of Horizon Therapeutics has notably contributed to its revenue stream, with Horizon products adding $1.1 billion in sales for the quarter. Despite macroeconomic headwinds ...